Fineline Cube

Follow:
14720 Articles
China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access
CompanyDeals

China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access

CompanyDrug

Zelgen’s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial – Dual JAK/ACVR1 Inhibitor Expands Beyond Myelofusion

Policy / Regulatory

China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program

CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China's NHL Market
CompanyDeals

CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China’s NHL Market

CompanyDeals

Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech

Zuellig Pharma Acquires Cialis Rights for Hong Kong, Macau, and South Korea from Eli Lilly
CompanyDeals

Zuellig Pharma Acquires Cialis Rights for Hong Kong, Macau, and South Korea from Eli Lilly

Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration
CompanyDeals

Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration

CompanyDeals

Tasly Pharma Partners with Beijing Neurosurgical Institute on Dual-Target CAR-T Therapy – RMB 240M Investment Advances CD44/CD133 Autologous Treatment for Recurrent Glioblastoma

Mannerchem Secures Exclusive China Rights to Kintor's AI-Discovered Whitening Ingredient Oximidol KT-939
CompanyDeals

Mannerchem Secures Exclusive China Rights to Kintor’s AI-Discovered Whitening Ingredient Oximidol KT-939

CompanyDrug

Youcare Pharmaceutical Advances Dual mRNA Vaccine Pipeline with NMPA Approvals for RSV and Herpes Zoster Candidates

GlycoNex and Nippon Kayaku Collaborate on Next-Generation Protease-Activated ADC GNX201 for Solid Tumors
CompanyDeals

GlycoNex and Nippon Kayaku Collaborate on Next-Generation Protease-Activated ADC GNX201 for Solid Tumors

CompanyDeals

Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M